Emanuela Palmerini, MD

Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses optimal patient selection for denosumab (Xgeva) in patients with giant cell tumor of bone (GCTB).

Patients who would benefit most from the treatment are those with advanced GCTB, Palmerini says. For example, a larger tumor of the pelvis. She discusses one 70-year-old patient who had a lesion going from the spine to the left iliac wing. This patient could not be treated with radiation therapy because of radiation-induced sarcoma. He underwent 4 years of denosumab and is now cured 4 years off trial.

Videos

Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses optimal patient selection for denosumab (Xgeva) in patients with giant cell tumor of bone.

Optimal Patient Selection for Denosumab in Giant Cell Tumor of Bone

Emanuela Palmerini, MD, Prometeo Laboratory: Clinical and Experimental Research Contract, Chemotherapy for Rare Musculoskeletal Tumors Department, Instituto Ortopedico Rizzoli, discusses efficacy results for denosumab (Xgeva) in patients with giant cell tumor of bone (GCTB).

Emanuela Palmerini, MD | Authors

Articles

Optimal Patient Selection for Denosumab in Giant Cell Tumor of Bone

Results for Denosumab in Patients With Giant Cell Tumor of Bone